Frontiers in Pharmacology (Dec 2019)
Long Non-Coding RNA in Drug Resistance of Non-Small Cell Lung Cancer: A Mini Review
- Ruizheng Sun,
- Ruizheng Sun,
- Ruizheng Sun,
- Ranran Wang,
- Siyuan Chang,
- Siyuan Chang,
- Siyuan Chang,
- Kexin Li,
- Kexin Li,
- Kexin Li,
- Rongsi Sun,
- Rongsi Sun,
- Rongsi Sun,
- Mengnan Wang,
- Mengnan Wang,
- Mengnan Wang,
- Zheng Li,
- Zheng Li,
- Zheng Li
Affiliations
- Ruizheng Sun
- Department of Pathology, Xiangya Hospital, Central South University, Changsha, China
- Ruizheng Sun
- NHC Key Laboratory of Carcinogenesis, Cancer Research Institute and School of Basic Medical, Central South University, Changsha, China
- Ruizheng Sun
- The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, China
- Ranran Wang
- Department of Cardiovascular Surgery, The Second Xiangya Hospital, Central South University, Changsha, China
- Siyuan Chang
- Department of Pathology, Xiangya Hospital, Central South University, Changsha, China
- Siyuan Chang
- NHC Key Laboratory of Carcinogenesis, Cancer Research Institute and School of Basic Medical, Central South University, Changsha, China
- Siyuan Chang
- The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, China
- Kexin Li
- Department of Pathology, Xiangya Hospital, Central South University, Changsha, China
- Kexin Li
- NHC Key Laboratory of Carcinogenesis, Cancer Research Institute and School of Basic Medical, Central South University, Changsha, China
- Kexin Li
- The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, China
- Rongsi Sun
- Department of Pathology, Xiangya Hospital, Central South University, Changsha, China
- Rongsi Sun
- NHC Key Laboratory of Carcinogenesis, Cancer Research Institute and School of Basic Medical, Central South University, Changsha, China
- Rongsi Sun
- The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, China
- Mengnan Wang
- Department of Pathology, Xiangya Hospital, Central South University, Changsha, China
- Mengnan Wang
- NHC Key Laboratory of Carcinogenesis, Cancer Research Institute and School of Basic Medical, Central South University, Changsha, China
- Mengnan Wang
- The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, China
- Zheng Li
- Department of Pathology, Xiangya Hospital, Central South University, Changsha, China
- Zheng Li
- NHC Key Laboratory of Carcinogenesis, Cancer Research Institute and School of Basic Medical, Central South University, Changsha, China
- Zheng Li
- The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, China
- DOI
- https://doi.org/10.3389/fphar.2019.01457
- Journal volume & issue
-
Vol. 10
Abstract
Lung cancer is one of main causes of cancer mortality and 83% of lung cancer cases are classified as non-small cell lung cancer (NSCLC). Patients with NSCLC usually have a poor prognosis and one of the leading causes is drug resistance. With the progress of drug therapy, the emergence and development of drug resistance affected the prognosis of patients severely. Accumulating evidence reveals that long non-coding RNAs (lncRNAs), as “dark matters” of the human genome, is of great significance to drug resistance in NSCLC. Herein, we review the role of lncRNAs in drug resistance in NSCLC.
Keywords
- long non-coding RNAs
- drug resistance
- non-small cell lung cancer
- cisplatin
- taxanes
- epidermal growth factor receptor tyrosine kinase inhibitors
